logo image
search icon
Antimicrobial Peptides Market

Antimicrobial Peptides Market Size, Share & Trends Analysis Report By Product (Plant Antimicrobial Peptides, Bacterial Antimicrobial Peptides, Animal Antimicrobial Peptides, Insect Antimicrobial Peptides), By Ailments, By Route of Administration, By End User, By Distribution Channel, By Region, And By Segment Forecasts, 2024-2031

Report ID : 2335 | Published : 2024-03-01 | Pages: 180 | Format: PDF/EXCEL

Antimicrobial Peptides Market Size is valued at USD 223.90 Mn in 2023 and is predicted to reach USD 532.02 Mn by the year 2031 at a 11.65% CAGR during the forecast period for 2024-2031.

Antimicrobial Peptides Market

AMPs possess the ability to eliminate microbial pathogens directly; others function indirectly by modulating host defense systems. Natural antimicrobial peptides are found in bacterial and eukaryotic defense systems. They defend against bacteria, viruses, and fungi. They target cytoplasmic membranes, cell walls, DNA, and proteins, hence their composition is crucial. Direct-to-Consumer genetic testing is in demand due to better understanding of its benefits, such as tracing ancestry, assessing sickness risks, and delivering personalized healthcare information. 

The increased awareness of medications and therapies incorporating antimicrobial peptides is anticipated to enhance the global market for such peptides significantly. Chronic conditions where antibiotic resistance remains ineffectual offer particularly attractive opportunities for antimicrobial peptide manufacturers. Moreover, continual advancements in biotechnology are streamlining the development and production processes of antimicrobial peptides, thereby facilitating market expansion. There is a growing acknowledgment of infection control measures, particularly within healthcare settings, driving the demand for antimicrobial peptides as effective solutions.

Additionally, persistent investments in research and development activities are driving the discovery and innovation of new antimicrobial peptides, thus maintaining market momentum. Additionally, stringent regulatory standards governing the approval process of antimicrobial peptides pose challenges, potentially leading to delays in market entry and increased development costs. Despite promising research findings, not all antimicrobial peptides smoothly transition from experimental stages to viable commercial products, introducing uncertainties regarding their market viability.

Competitive Landscape

Some Major Key Players In The Antimicrobial Peptides Market:

  • Novozymes A/S
  • Polypeptide Group
  • Bachem Holding AG
  • Wuxi Apptec
  • Ana Spec Inc. (a Eurofins Company)
  • Merial
  • Ipsen S.A.
  • AstraZeneca
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • Sandoz International GmbH
  • Polymedia
  • Magennis Inc.
  • Probiotic Limited
  • Eli Lilly and Company
  • Johnson & Johnson Private Limited
  • Melinta Therapeutics, LLC
  • Vertex Pharmaceuticals Incorporated
  • AMP Biotech
  • Phoenix Biotechnology Inc.
  • Novabiotics
  • Other prominent players

Market Segmentation:

 

The antimicrobial peptides market is categorized on the basis of product , ailments distribution channel, route of administration and end users .Based on product, the antimicrobial peptides market is segmented as plant antimicrobial peptides, bacterial antimicrobial peptides, animal antimicrobial peptides, and insect antimicrobial peptides .Based on Ailments, the market is segmented as pneumonia, hepatitis, bacterial infections, HIV). Based on Distribution Channel, the Antimicrobial Peptides market is segmented as Hospital, Research Institutes, Specialty Clinic, and Pharmacies. Based on route of administration the antimicrobial peptides market is segmented as topical, subcutaneous, intravenous, Based on end users. the antimicrobial peptides market is divided into pharma and healthcare, the agriculture industry, and biological engineering.

Based On End Users, The Pharma And Healthcare Segment Is Accounted As A Major Contributor To The Antimicrobial Peptides Market.

The Pharma and Healthcare category is expected to hold a major share of the global Antimicrobial Peptides Market in 2022. Pharmaceutical firms are becoming more aware of the promise of AMPs as innovative medicinal agents. They may be involved in the research, development, and production of AMP-based drugs to address bacterial infections. These companies may either develop AMPs in-house or collaborate with biotechnology firms specializing in peptide therapeutics. The increasing adoption of AMPs by Pharma and Healthcare as end users reflects the growing recognition of AMPs as valuable tools in the fight against bacterial infections and the need for innovative therapeutic options in the field of antimicrobial therapy.

The Hospitals Segment Witnessed Rapid Growth.

The hospital segment is projected to develop at a rapid rate in the global antimicrobial peptides market. Hospitals are increasingly playing a more prominent role in the distribution of antimicrobial peptides (AMPs). Traditionally, pharmaceutical products, including antimicrobial agents, were primarily distributed through pharmaceutical wholesalers and distributors. However, as the demand for specialized therapeutic products like AMPs grows, hospitals are increasingly becoming direct purchasers and distributors of these products.

In The Region, The North America Antimicrobial Peptides Market Holds A Significant Revenue Share.

The North American Antimicrobial Peptides Market: the market is projected to record a large market revenue share. The anticipated surge in demand for antibiotics within this geographic area, coupled with a rise in research and development endeavors, is projected to propel the industry forward throughout the forecast period. Additionally, the Asia Pacific regional market is poised to witness the most rapid growth, attributable to factors such as the escalating prevalence of diverse infectious diseases, a burgeoning elderly population, and an upsurge in patient awareness regarding their health.

Recent Developments:

  • In Jul 2023, Bio Cote Limited and Eco Finish formed a strategic agreement to incorporate Bio Cote technology into antimicrobial surfaces for residential and commercial pools. This partnership delivers antimicrobial additives designed to inhibit the proliferation of bacteria, algae, viruses, and other microbes, enhancing safety and protection for swimmers in pool settings.
  • In July 2022, Boehringer Ingelheim, Evotec SE, and biome Rieux collaborated to create a joint venture with the aim of promoting the discovery of innovative antimicrobials to address antimicrobial resistance. This alliance combines the knowledge of both entities to develop creative solutions.

Antimicrobial Peptides Market Report Scope

Report Attribute

Specifications

Market Size Value In 2023

USD 223.90 Mn

Revenue Forecast In 2031

USD 532.02 Mn

Growth Rate CAGR

CAGR of 11.65% from 2024 to 2031

Quantitative Units

Representation of revenue in US$ Million and CAGR from 2024 to 2031

Historic Year

2019 to 2023

Forecast Year

2024-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Product, Ailments, Route of Administration, Distribution Channel, End User,

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea

Competitive Landscape

Novozymes A/S, Polypeptide Group, Bachem Holding AG, Wuxi Apptec, Ana Spec Inc. (a Eurofins Company), Merial, Ipsen S.A., AstraZenec, Pfizer Inc, GlaxoSmithKline plc, Merck & Co. Inc., Sandoz International GmbH, Polymedia, Magennis Inc., Probiotic Limited Melinta Therapeutics, LLC, Vertex Pharmaceuticals Incorporated, AMP Biotech, Phoenix Biotechnology Inc., Novabiotics and Others

Customization Scope

Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Antimicrobial Peptides Market Snapshot

Chapter 4. Global Antimicrobial Peptides Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Product Type Estimates & Trend Analysis

5.1. by Product Type & Market Share, 2019 & 2031

5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Product Type:

5.2.1. Plant Antimicrobial Peptides

5.2.2. Bacterial Antimicrobial Peptides

5.2.3. Animal Antimicrobial Peptides

5.2.4. Insect Antimicrobial Peptides

Chapter 6. Market Segmentation 2: by Ailments Estimates & Trend Analysis

6.1. by Ailments & Market Share, 2019 & 2031

6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Ailments:

6.2.1. Pneumonia

6.2.2. Hepatitis

6.2.3. Bacterial infections

6.2.4. HIV

Chapter 7. Market Segmentation 3: by Route of Administration Estimates & Trend Analysis

7.1. by Route of Administration & Market Share, 2019 & 2031

7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Route of Administration:

7.2.1. Topical

7.2.2. Subcutaneous

7.2.3. Intravenous

Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis

8.1. By End User & Market Share, 2019 & 2031

8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By End User:

8.2.1. Pharma and Healthcare

8.2.2. Agriculture Industry

8.2.3. Biological Engineering

8.2.4. Others

Chapter 9. Market Segmentation 5: by Distribution Channel Estimates & Trend Analysis

9.1. by Distribution Channel & Market Share, 2019 & 2031

9.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Distribution Channel:

9.2.1. Hospital

9.2.2. Research Institutes

9.2.3. Specialty Clinic

9.2.4. Pharmacies

Chapter 10. Antimicrobial Peptides Market Segmentation 6: Regional Estimates & Trend Analysis

10.1. North America

10.1.1. North America Antimicrobial Peptides Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2019-2031

10.1.2. North America Antimicrobial Peptides Market Revenue (US$ Million) Estimates and Forecasts by Ailments, 2019-2031

10.1.3. North America Antimicrobial Peptides Market revenue (US$ Million) by Route of Administration, 2019-2031

10.1.4. North America Antimicrobial Peptides Market revenue (US$ Million) By End User, 2019-2031

10.1.5. North America Antimicrobial Peptides Market revenue (US$ Million) by Distribution Channel, 2019-2031

10.1.6. North America Antimicrobial Peptides Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031

10.2. Europe

10.2.1. Europe Antimicrobial Peptides Market revenue (US$ Million) by Product Type, 2019-2031

10.2.2. Europe Antimicrobial Peptides Market revenue (US$ Million) by Ailments, 2019-2031

10.2.3. Europe Antimicrobial Peptides Market revenue (US$ Million) by Route of Administration, 2019-2031

10.2.4. Europe Antimicrobial Peptides Market revenue (US$ Million) By End User, 2019-2031

10.2.5. Europe Antimicrobial Peptides Market revenue (US$ Million) by Distribution Channel, 2019-2031

10.2.6. Europe Antimicrobial Peptides Market revenue (US$ Million) by country, 2019-2031

10.3. Asia Pacific

10.3.1. Asia Pacific Antimicrobial Peptides Market revenue (US$ Million) by Product Type, 2019-2031

10.3.2. Asia Pacific Antimicrobial Peptides Market revenue (US$ Million) by Ailments, 2019-2031

10.3.3. Asia-Pacific Antimicrobial Peptides Market revenue (US$ Million) by Route of Administration, 2019-2031

10.3.4. Asia Pacific Antimicrobial Peptides Market revenue (US$ Million) By End User, 2019-2031

10.3.5. Asia Pacific Antimicrobial Peptides Market revenue (US$ Million) by Distribution Channel, 2019-2031

10.3.6. Asia Pacific Antimicrobial Peptides Market revenue (US$ Million) by country, 2019-2031

10.4. Latin America

10.4.1. Latin America Antimicrobial Peptides Market revenue (US$ Million) by Product Type, 2019-2031

10.4.2. Latin America Antimicrobial Peptides Market revenue (US$ Million) by Ailments, 2019-2031

10.4.3. Latin America Antimicrobial Peptides Market revenue (US$ Million) by Route of Administration, 2019-2031

10.4.4. Latin America Antimicrobial Peptides Market revenue (US$ Million) By End User, 2019-2031

10.4.5. Latin America Antimicrobial Peptides Market revenue (US$ Million) by Distribution Channel, 2019-2031

10.4.6. Latin America Antimicrobial Peptides Market revenue (US$ Million) by country, 2019-2031

10.5. Middle East & Africa

10.5.1. Middle East & Africa Antimicrobial Peptides Market revenue (US$ Million) by Product Type, 2019-2031

10.5.2. Middle East & Africa Antimicrobial Peptides Market revenue (US$ Million) by Ailments, 2019-2031

10.5.3. Middle East & Africa Antimicrobial Peptides Market revenue (US$ Million) by Route of Administration, 2019-2031

10.5.4. Middle East & Africa Antimicrobial Peptides Market revenue (US$ Million) By End User, 2019-2031

10.5.5. Middle East & Africa Antimicrobial Peptides Market revenue (US$ Million) by Distribution Channel, 2019-2031

10.5.6. Middle East & Africa Antimicrobial Peptides Market revenue (US$ Million) by country, 2019-2031

Chapter 11. Competitive Landscape

11.1. Major Mergers and Acquisitions/Strategic Alliances

11.2. Company Profiles

11.2.1. Novozymes A/S

11.2.2. Polypeptide Group

11.2.3. Bachem Holding AG

11.2.4. Wuxi Apptec

11.2.5. Ana Spec Inc. (a Eurofins Company)

11.2.6. Merial

11.2.7. Ipsen S.A.

11.2.8. AstraZeneca

11.2.9. Pfizer Inc.

11.2.10. GlaxoSmithKline plc

11.2.11. Merck & Co. Inc.

11.2.12. Sandoz International GmbH

11.2.13. Polymedia

11.2.14. Magennis Inc.

11.2.15. Probiotic Limited

11.2.16. Eli Lilly and Company

11.2.17. Johnson & Johnson Private Limited

11.2.18. Melinta Therapeutics, LLC

11.2.19. Vertex Pharmaceuticals Incorporated

11.2.20. AMP Biotech

11.2.21. Phoenix Biotechnology Inc.

11.2.22. Novabiotics

11.2.23. Other prominent players

Segmentation of Antimicrobial Peptides Market:

Antimicrobial Peptides Market By Product

  • Plant Antimicrobial Peptides
  • Bacterial Antimicrobial Peptides
  • Animal Antimicrobial Peptides
  • Insect Antimicrobial Peptides

Antimicrobial Peptides Market Seg

Antimicrobial Peptides Market By Ailments

  • Pneumonia
  • Hepatitis
  • Bacterial infections
  • HIV

Antimicrobial Peptides Market By Route of Administration

  • Topical
  • Subcutaneous
  • Intravenous

Antimicrobial Peptides Market By End User

  • Pharma and Healthcare
  • Agriculture Industry
  • Biological Engineering
  • Others

Antimicrobial Peptides Market By Distribution Channel

  • Hospital
  • Research Institutes
  • Specialty Clinic
  • Pharmacies

Antimicrobial Peptides Market By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Antimicrobial Peptides Market Size?

Antimicrobial Peptides Market is expected to grow at a 11.65% CAGR during the forecast period for 2024-2031.

Polymedia, Magennis Inc., Probiotic Limited Melinta Therapeutics, LLC, Vertex Pharmaceuticals Incorporated, AMP Biotech, Phoenix Biotechnology Inc., O

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach